Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 9/20 | 0.53 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.53 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.53 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060528 | 1.00 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9874277 | 1.00 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9874273 | 1.00 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9877701 | 0.89 | ABCC9 (0.45) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9736978 | 0.89 | ABCC9 (0.43) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9875883 | 0.87 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9875895 | 0.87 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9875873 | 0.87 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL8137096 | 0.85 | ABCC9 (0.39) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9876177 | 0.85 | ABCC9 (0.41) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5071871-A | Pharmaceutically useful benzo(β)pyranes and pyranopyridines | SANDOZ LTD. (CH) | 1991-12-10 | — | — | US | claimed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20220313664-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | ASSETSUP (FR) | 2022-10-06 | — | — | US | disclosed |
| US-20220265282-A1 | USE OF REMOTE ISCHEMIC CONDITIONING FOR TRAUMATIC INJURY | THE HOSPITAL FOR SICK CHILDREN (CA) | 2022-08-25 | — | — | US | disclosed |
| EP-4031134-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | UNIVERSITE DE BORDEAUX (FR) | 2022-07-27 | — | — | EP | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-5071871-A | Pharmaceutically useful benzo(β)pyranes and pyranopyridines | SANDOZ LTD. (CH) | 1991-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | ABCC9 633/4885ABCC8 1479/4885KCNJ11 38/4885 |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | KCNN3, KCNN1, KCNN2 | ABCC9 1065/4885ABCC8 1310/4885KCNJ11 9/4885 |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | ABCC9 2553/4885ABCC8 2394/4885KCNJ11 3735/4885 |
| US-20220313664-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | KCNN3, KCNN1, KCNN2 | ABCC9 2208/4885ABCC8 2726/4885KCNJ11 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.